SynthesisOral diseases2026
Mucoadhesive Drug Delivery Systems for Oral Chronic Inflammatory Mucosal Diseases. The Future is Already Present. A Systematic Review.
Synthesis in Oral diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- High Value-Added Secondary Raw Material From Winemaking Waste Bentonite to Design Antioxidant Pectin-Based Mucoadhesive Buccal Films.ChemistryOpen · 2026Article
- Solid lipid microparticles-into-film delivering clobetasol: from buccal formulation design to pilot clinical study in patients with oral lichen planus.Drug delivery and translational research · 2026Article
- Review
- Mucoadhesive Buccal Patches Containing Resveratrol and/or Erythromycin-Loaded Lipid Microparticles as a Potential Targeted Strategy for the Prevention and Management of MRONJ in Patients Undergoing Oral Surgery.Antibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOral lichen planus (OLP) and recurrent aphthous stomatitis (RAS) are considered the most painful oral inflammatory diseases, with high global prevalence and significant impacts on patients' quality of life. In the last decades, researchers have been exploring mucoadhesive drug delivery systems (MDDS) to improve drugs safety and efficacy through optimized formulations for enhancing patients compliance while addressing the limitations of semisolid products.
objectiveTo assess the clinical efficacy of different MDDS (e.g., tablets, films, and patches) in treating OLP or RAS by a revision of the literature.
methodsAccording to PRISMA guidelines, the study assessed the remission of signs and symptoms in terms of decreasing burning sensation, pain severity, and lesion size. The protocol was registered on the PROSPERO database (CRD42024603173) and records identified by Medline/PubMed/Scopus.
resultsThirteen observational studies involving humans affected by OLP or RAS were included. The absence of standardized therapies in terms of MDDS, drug, and dosing regimen was highlighted. All MDDS offered several benefits, including prolonged drug release, protection from mechanical irritation, and pain and inflammation reduction. MDDS improved patients' adherence by minimizing daily applications and systemic side effects.
conclusionsMDDS may represent a promising option for both OLP and RAS treatments, addressing key limitations of traditional formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.